These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38976182)

  • 1. Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement.
    Tanegashima T; Shiota M; Kimura T; Takamatsu D; Matsui Y; Yokomizo A; Saito R; Morizane S; Miyake M; Tsutsumi M; Yamamoto Y; Tashiro K; Tomida R; Edamura K; Narita S; Yamaguchi T; Kasahara T; Hashimoto K; Kato M; Yoshino T; Akamatsu S; Matsukawa A; Kaneko T; Matsumoto R; Joraku A; Kato M; Saito T; Kato T; Tatarano S; Sakamoto S; Kanno H; Terada N; Nishiyama N; Kitamura H; Eto M;
    Int J Clin Oncol; 2024 Oct; 29(10):1586-1593. PubMed ID: 38976182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer.
    Shiota M; Takamatsu D; Kimura T; Tashiro K; Matsui Y; Tomida R; Saito R; Tsutsumi M; Yokomizo A; Yamamoto Y; Edamura K; Miyake M; Morizane S; Yoshino T; Matsukawa A; Narita S; Matsumoto R; Kasahara T; Hashimoto K; Matsumoto H; Kato M; Akamatsu S; Joraku A; Kato M; Yamaguchi T; Saito T; Kaneko T; Takahashi A; Kato T; Sakamoto S; Enokida H; Kanno H; Terada N; Suekane S; Nishiyama N; Eto M; Kitamura H;
    Cancer Sci; 2022 Jul; 113(7):2386-2396. PubMed ID: 35485635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer.
    Jegadeesh N; Liu Y; Zhang C; Zhong J; Cassidy RJ; Gillespie T; Kucuk O; Rossi P; Master VA; Alemozaffar M; Jani AB
    Cancer; 2017 Feb; 123(3):512-520. PubMed ID: 27859018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy.
    Bravi CA; Droghetti M; Fossati N; Gandaglia G; Suardi N; Mazzone E; Cucchiara V; Scuderi S; Barletta F; Schiavina R; Osmonov D; Juenemann KP; Boeri L; Karnes RJ; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Grubmüller B; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol Oncol; 2022 Jun; 5(3):285-295. PubMed ID: 34176768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen associates with extensive lymph node invasion in high-risk prostate cancer.
    Porcaro AB; Corsi P; Inverardi D; Sebben M; Tafuri A; Processali T; Mattevi D; De Marchi D; Pirozzi M; Cerruto MA; Amigoni N; Rizzetto R; Brunelli M; Siracusano S; Artibani W
    Tumori; 2018 Aug; 104(4):307-311. PubMed ID: 29714659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.
    Suardi N; Gandaglia G; Gallina A; Di Trapani E; Scattoni V; Vizziello D; Cucchiara V; Bertini R; Colombo R; Picchio M; Giovacchini G; Montorsi F; Briganti A
    Eur Urol; 2015 Feb; 67(2):299-309. PubMed ID: 24571959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mid-term oncologic outcomes of radical prostatectomy in lymph node metastatic prostate cancer patients.
    Berchiche W; Long Depaquit T; Baboudjian M; Barret É; Rozet F; Cathelineau X; Bastide C
    Prog Urol; 2023 Aug; 33(8-9):437-445. PubMed ID: 37248105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
    Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
    Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
    Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D
    Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
    Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A
    Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy.
    Milenkovic U; Kuijk J; Roussel E; Devos G; Van den Broeck T; Van Eecke H; Vanderstichele A; Duvillier T; Verhamme L; Van Haute W; Goeman L; Berghen C; Joniau S; De Meerleer G
    Eur Urol Oncol; 2023 Dec; 6(6):582-589. PubMed ID: 36878753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of Lymph Node Invasion in Patients with Clinically Localized Prostate Cancer Who Undergo Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: The Role of Obesity.
    Tafuri A; Rizzetto R; Amigoni N; Sebben M; Shakir A; Gozzo A; Odorizzi K; Gallina S; Bianchi A; Ornaghi P; Brunelli M; Migliorini F; Cerruto MA; Artibani W; Siracusano S; Antonelli A; Porcaro AB
    Urol Int; 2021; 105(5-6):362-369. PubMed ID: 33059351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective lymph node dissection for castration-resistant prostate cancer.
    Busch J; Hinz S; Kempkensteffen C; Erber B; Klopf C; Weikert S; Miller K; Magheli A
    Urol Int; 2012; 88(4):441-6. PubMed ID: 22398510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
    Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
    Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
    Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM
    Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy.
    Kim D; Kim DY; Kim JS; Hong SK; Byun SS; Lee SE
    PLoS One; 2021; 16(9):e0256778. PubMed ID: 34506516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
    Preisser F; Bandini M; Marchioni M; Nazzani S; Tian Z; Pompe RS; Fossati N; Briganti A; Saad F; Shariat SF; Heinzer H; Huland H; Graefen M; Tilki D; Karakiewicz PI
    Prostate; 2018 May; 78(6):469-475. PubMed ID: 29460290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.